Earnings Call · Q4 FY2022·2023-02-28

Q4 22EPS +8.15%·Rev n/aQ3 22EPS -8.11%·Rev n/aQ2 22EPS -96.67%·Rev n/aQ1 22EPS +45.63%·Rev n/a⚠ consensus missing

Sarepta Therapeutics, Inc. SRPT

Mary Jenkins — Associate Director, Investor Relations

Doug Ingram — President and Chief Executive Officer

Louise Rodino-Klapac — Senior Vice President, Research and Development

Dallan Murray — Chief Commercial Officer

Ian Estepan — Chief Financial Officer

+1.4%1d on move date+0.7% vs SPY3d+3.5%5d+10.6%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SRPT calls or request research access.

More SRPT calls Browse calls Request research access